Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Neurology. 1999 Oct 22;53(7):1588-9.

    Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.

    Source

    Department of Neurological Sciences, Università La Sapienza, Rome, Italy.

    Abstract

    We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.

    Comment in

    PMID:
    10534275
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for HighWire

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk